drugset
drugset / Trial / NCT00563524

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

NCT00563524 ↗

Phase 1 Completed 76 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis

Timeline

Start
2007-12-20
Primary completion
2010-06-14
Completion
2010-06-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator FEZAKINUMAB Monoclonal antibody — Subcutaneous

Indications

psoriasis